OneCell Diagnostics, a Cupertino, CA- and Mumbai, India-based genomics-based precision oncology company, raised $16M in Series A Funding.
The round was led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon Ventures, and Singularity Ventures. Celesta Capital Founding Managing Partner Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr. James Rothman will join the OneCell board of directors.
The company intends to use the funds to expand to the U.S. market with its next-generation liquid biopsy test, OncoIndx Ikon.
Led by CEO Mohan Uttarwar, OneCell Diagnostics is a genomics-based precision oncology company, providing comprehensive genomic solutions for better cancer management. Its proprietary technology leverages a combination of sequencing in combination with bioinformatics, AI / ML, and data-analytics for multi-omics biomarkers. Their cancer screening tests are based on a proprietary Circulating Tumor Cell (CTC) and True-Single-Cell-Multi-omics platform, supporting a range of applications in clinical cancer care and early-stage clinical trials for biotech and pharma companies. OneCell’s cell biopsy technology integrates CTC-DNA with CTC-RNA and cell surface protein testing, all from a single blood draw, a significant advancement over current “liquid biopsy” testing.
Its operations are headquartered in Silicon Valley and India.
FinSMEs
22/11/2024